XOMA Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
121,649.00
78,445.00
66,263.00
25,742.00
43,471.00
45,780
Total Accounts Receivable
3,781.00
3,309.00
4,069.00
566.00
397.00
1,468
Other Current Assets
1,630.00
2,088.00
1,887.00
852.00
327.00
378
Total Current Assets
127,060.00
83,842.00
72,219.00
27,160.00
44,195.00
47,626
Net Property, Plant & Equipment
6,456.00
5,120.00
1,997.00
1,036.00
83.00
59
Other Assets
1,266.00
669.00
664.00
481.00
657.00
708
Total Assets
134,782.00
89,631.00
74,880.00
28,677.00
44,935.00
63,785
ST Debt & Current Portion LT Debt
5,835.00
19,247.00
6,019.00
17,959.00
-
Accounts Payable
9,616.00
5,990.00
6,831.00
5,689.00
1,679.00
Income Tax Payable
-
-
-
-
1,637.00
Other Current Liabilities
14,194.00
11,238.00
10,445.00
8,858.00
4,106.00
Total Current Liabilities
29,645.00
36,475.00
23,295.00
32,506.00
7,422.00
Long-Term Debt
35,150.00
16,290.00
42,930.00
25,381.00
14,572.00
Provision for Risks & Charges
-
31,828.00
-
-
-
Other Liabilities
73,974.00
1,939.00
10,964.00
18,000.00
17,155.00
Total Liabilities
138,769.00
86,532.00
77,189.00
75,887.00
39,149.00
Common Equity (Total)
3,987.00
3,099.00
2,309.00
47,210.00
5,786.00
Total Shareholders' Equity
3,987.00
3,099.00
2,309.00
47,210.00
5,786.00
Total Equity
3,987.00
3,099.00
2,309.00
47,210.00
5,786.00
Liabilities & Shareholders' Equity
134,782.00
89,631.00
74,880.00
28,677.00
44,935.00

About XOMA

View Profile
Address
2200 Powell Street
Emeryville California 94608
United States
Employees -
Website http://www.xoma.com
Updated 07/08/2019
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J.